The EPS beat and accelerating YCANTH unit growth are positive, but widening operating losses and cash burn ($9.5M in Q1) limit upside. Watch for the second Phase 3 common warts trial initiation in mid-2026 and any partnership announcements for EU commercialization as potential catalysts.
Price Chart
Executive Summary
Verrica reported Q1 2026 revenue of $5.0M (above $4.5M consensus) and a GAAP net loss of $0.45/share, beating the $-0.59 consensus estimate by 22%. YCANTH dispensed units grew 51% YoY to 15,302, and the company achieved >50% enrollment in the first Phase 3 common warts trial. However, operating losses widened to $9.7M from $8.1M a year ago, and cash burn reduced the cash balance to $20.6M from $30.1M at year-end.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $5.0M vs $3.4M YoY; product revenue $4.3M (+25.4% YoY)
- GAAP EPS -$0.45 vs consensus -$0.59 (22% beat); net loss $9.7M unchanged YoY
- YCANTH dispensed units 15,302, up 51.3% YoY and 12.1% sequentially
- Cash and equivalents $20.6M at March 31, 2026, down from $30.1M at Dec 31, 2025
- Over 50% of targeted enrollment achieved in first Phase 3 common warts trial (COVE-2)
- Japan launch by Torii Pharmaceutical represents first ex-U.S. market
- SG&A expenses rose to $10.0M from $8.8M YoY on sales force expansion
- R&D expenses $3.9M vs $2.3M YoY, driven by Phase 3 common warts program
Financial Impact
Revenue beat consensus by ~$0.5M (11%); EPS beat by $0.14 (22%); net loss unchanged at $9.7M but per-share improved due to share count doubling
Risk Factors
- Cash runway only into Q1 2027; may need additional financing before profitability
- Phase 3 common warts program may fail to replicate Phase 2 results
- Competition from other molluscum treatments could slow YCANTH adoption
- Dependence on Torii partnership for Japan revenue and Phase 3 funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-219395 |
| Document: d152529d8k.htm | 0001193125-26-219395 |
| Document: 0001193125-26-219395-index-headers.html | 0001193125-26-219395 |
| Document: 0001193125-26-219395-index.html | 0001193125-26-219395 |
| Document: 0001193125-26-219395.txt | 0001193125-26-219395 |
| 8-K Data (Synthetic) | 0001193125-26-219395 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Press Release | $4.95 $4.18 | ▼ −15.56% | ▼ −17.68% | $3.42 (−30.91%) |
Jun 9, 2026 19w ago | 8-K | $5.75 $6.53 | ▲ +13.57% | ▲ +9.94% | $3.42 (−40.52%) |
May 12, 2026 23w ago | 8-K | $7.37 $6.03 | ▼ −18.25% | ▼ −17.64% | $3.42 (−53.60%) |
May 12, 2026 23w ago | Press Release | $7.37 $6.03 | ▼ −18.25% | ▼ −17.64% | $3.42 (−53.60%) |
Apr 20, 2026 27w ago | DEFA14A | $6.32 $5.87 | ▼ −7.12% | ▼ −12.04% | $3.42 (−45.89%) |
Mar 11, 2026 32w ago | Press Release | $6.26 $5.83 | ▼ −6.87% | ▼ −7.39% | $3.42 (−45.37%) |
Mar 4, 2026 33w ago | Court Ruling | $5.20 $5.47 | ▼ −5.19% | ▼ −8.67% | $3.42 (+34.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers